Walgreens Reports Profit Decline but Sales, Guidance Rise
April 05 2016 - 8:12AM
Dow Jones News
By Lisa Beilfuss
Walgreens Boots Alliance Inc. said sales increased 14% in its
latest quarter and the company bumped up its full-year guidance,
though profit declined as the largest pharmacy chain in the U.S.
came up against a tough comparison.
The Deerfield, Ill., company in October struck a $9.4 billion
deal to buy America's third-biggest pharmacy chain Rite Aid Corp.
in a move to more than double its store count. That deal, which is
under regulatory review by the Federal Trade Commission, is still
expected to close in the second half of this year, Walgreens said
Tuesday.
The deal is part of a broader consolidation in the drugstore
space, as pharmacies face lower reimbursement rates from health
insurers and the federal government in addition to growing
competition from the likes of Wal-Mart.
Walgreens said Tuesday that profit in its most recent quarter
fell to $930 million, or 85 cents a share, down from year-earlier
earnings of $2.04 billion, or $1.93 a share -- a tough comparison
because of a gain of $814 million, or 77 cents a share, related to
its 2014 deal to buy the chunk of Europe's Alliance Boots GmbH that
it didn't already own.
Excluding the merger-related gain, among other items, per-share
profit rose to $1.31 from $1.18. Analysts anticipated $1.28 in
adjusted earnings per share.
Thanks in large part to the acquisition, overall sales at
Walgreens jumped 14% from a year earlier to $30.18 billion as sales
at stores open at least a year rose 2.2% from a year earlier.
Pharmacy sales, which represent about two-thirds of the top line,
rose 3.2% as the company filled 233 million prescriptions, up 3.9%
from a year earlier despite a weak cold and flu season. Analysts
expected $30.66 billion in total sales for the quarter. Walgreens
said adverse foreign exchange rates shaved 2.4% off its top
line.
For the fiscal year ending in August, the company projects $4.35
to $4.55 in adjusted earnings per share. Earlier, the low end of
that range was $4.35. Analysts have projected $4.48 a share.
Chief Executive Stefano Pessina said Tuesday that the company is
making good progress on its efforts to mitigate lower pharmacy
reimbursement rates and a challenging retail sales environment. In
its latest bid to capture a bigger piece of the prescription drug
market, Walgreens last month agreed to a deal with UnitedHealth
Group Inc.'s OptumRx by which OptumRx will charge its customers,
including employers and insurers, less for certain drugs if
patients fill their prescriptions at Walgreens stores.
Shares in the company, up 1.4% this year through Monday's close,
were inactive premarket.
Write to Lisa Beilfuss at lisa.beilfuss@wsj.com
(END) Dow Jones Newswires
April 05, 2016 07:57 ET (11:57 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Rite Aid (NYSE:RAD)
Historical Stock Chart
From Apr 2024 to May 2024
Rite Aid (NYSE:RAD)
Historical Stock Chart
From May 2023 to May 2024